Photo of Ming Hui Chen, MD, MMSc

Ming Hui Chen, MD, MMSc

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 355-8366
Fax: (617) 734-9930


MingHui.Chen@CARDIO.CHBOSTON.ORG

Photo of Ming Hui Chen, MD, MMSc

Brigham And Women's Hospital
Phone: (617) 355-8366
Fax: (617) 734-9930


MingHui.Chen@CARDIO.CHBOSTON.ORG

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Ming Hui Chen, MD, MMSc but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Ming Hui Chen, MD, MMSc

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Pediatrics, Harvard Medical School
  • Director, Cardiovascular Health for Cancer Survivors Clinic, Cardiology, Children's Hospital of Boston

DF/HCC PROGRAM AFFILIATION

Research Abstract

Research focuses on the diagnosis and amelioration of late cardiac effects in cancer survivors and understanding treatment-related cardiac effects in patients currently undergoing cancer treatment. Ongoing studies include: 1) the use of noninvasive imaging to detect and manage radiation-induced heart disease in long-term Hodgkin’s Disease survivors and 2) the cardiac effects of new experimental cancer therapies such as SU11248. Previous research, supported by the American Heart Association, explored ways of modifying radiation therapy delivery to decrease cardiotoxicity during breast cancer treatment. Additional interests include assessing disease prevalence amongst diverse populations.

Publications

Powered by Harvard Catalyst
  • Ryan TD, Border WL, Baker-Smith C, Barac A, Bock MJ, Canobbio MM, Choueiter NF, Chowdhury D, Gambetta KE, Glickstein JS, Kondapalli L, Mital S, Peiris V, Schiff RJ, Spicer RL, Towbin JA, Chen MH. The landscape of cardiovascular care in pediatric cancer patients and survivors: a survey by the ACC Pediatric Cardio-Oncology Work Group. Cardiooncology 2020; 5:16. PubMed
  • Tilki D, Chen MH, Wu J, Huland H, Graefen M, Braccioforte M, Moran BJ, D'Amico AV. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality. JAMA Oncol 2018. PubMed
  • Royce TJ, Chen MH, Wu J, Loffredo M, Renshaw AA, Kantoff PW, D'Amico AV. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2017. PubMed
  • Armenian SH, Hudson MM, Chen MH, Colan SD, Lindenfeld L, Mills G, Siyahian A, Gelehrter S, Dang H, Hein W, Green DM, Robison LL, Wong FL, Douglas PS, Bhatia S. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk BMC Cardiovasc Disord 2016; 16:187. PubMed
  • Martin NE, Chen MH, Zhang D, Richie JP, D'Amico AV. Unfavorable Intermediate-Risk Prostate Cancer and the Odds of Upgrading to Gleason 8 or Higher at Prostatectomy. Clin Genitourin Cancer 2016. PubMed
  • Braunstein LZ, Chen MH, Dosoretz DE, Salenius SA, Katin MJ, Nanda A, D'Amico AV. Whole Pelvis Versus Prostate-Only Radiotherapy With or Without Short-Course Androgen Deprivation Therapy and Mortality Risk. Clin Genitourin Cancer 2015. PubMed
  • Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys 2015; 93:828-35. PubMed
  • Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico AV. Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death. Eur Urol 2015. PubMed
  • Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy. Brachytherapy 2015. PubMed
  • Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 2015. PubMed
  • Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D'Amico AV. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease. Cancer 2015. PubMed
  • Cheney MD, Zhang D, Chen MH, Loffredo MJ, Richie JP, D'Amico AV. Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy. Clin Genitourin Cancer 2015; 13:338-43. PubMed
  • Chandra RA, Chen MH, Zhang D, Loffredo M, D'Amico AV. Age, Comorbidity, and the Risk of Prostate Cancer-Specific Mortality in Men With Biopsy Gleason Score 4+3: Implications on Patient Selection for Multiparametric MRI. Clin Genitourin Cancer 2015; 13:400-5. PubMed
  • Tanguturi SK, Lyatskaya Y, Chen Y, Catalano PJ, Chen MH, Yeo WP, Marques A, Truong L, Yeh M, Orlina L, Wong JS, Punglia RS, Bellon JR. Prospective assessment of deep inspiration breath-hold using 3-dimensional surface tracking for irradiation of left-sided breast cancer. 2015. PubMed
  • Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer. JAMA Oncol 2015; 1:334-40. PubMed
  • Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, Nathan PC, Tissing WJ, Shankar S, Sieswerda E, Skinner R, Steinberger J, van Dalen EC, van der Pal H, Wallace WH, Levitt G, Kremer LC, . Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015; 16:e123-36. PubMed
  • Parekh A, Chen MH, Graham P, Mahal BA, Hirsch AE, Nakabayashi M, Evan C, Kantoff PW, Martin NE, Nguyen PL. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. Clin Genitourin Cancer 2015. PubMed
  • Aizer AA, Gu X, Chen MH, Choueiri TK, Martin NE, Efstathiou JA, Hyatt AS, Graham PL, Trinh QD, Hu JC, Nguyen PL. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw 2015; 13:61-8. PubMed
  • Ennis KY, Chen MH, Smith GC, D'Amico AV, Zhang Y, Quinn SA, Ryemon SN, Goltz D, Harrison LB, Ennis RD. The Impact of Economic Recession on the Incidence and Treatment of Cancer. J Cancer 2015; 6:727-33. PubMed
  • Vance TM, Azabdaftari G, Pop EA, Lee SG, Su LJ, Fontham ET, Bensen JT, Steck SE, Arab L, Mohler JL, Chen MH, Koo SI, Chun OK. Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants. Prostate Cancer 2015; 2015:728046. PubMed
  • Chen MH, Blackington LH, Zhou J, Chu TF, Gauvreau K, Marcus KJ, Fisher DC, Diller LR, Ng AK. Blood pressure is associated with occult cardiovascular disease in prospectively studied Hodgkin lymphoma survivors after chest radiation. Leuk Lymphoma 2014. PubMed
  • Phillips JG, Aizer AA, Chen MH, Zhang D, Hirsch MS, Richie JP, Tempany CM, Williams S, Hegde JV, Loffredo MJ, D'Amico AV. The effect of differing Gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer. Clin Genitourin Cancer 2014. PubMed
  • Rose BS, Chen MH, Zhang D, Hirsch MS, Richie JP, Chang SL, Hegde JV, Loffredo MJ, D'Amico AV. Maximum tumor diameter and the risk of prostate-specific antigen recurrence after radical prostatectomy. Clin Genitourin Cancer 2014. PubMed
  • Pashtan I, Chen MH, D'Amico AV. The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml. 2014; 38:613-8. PubMed
  • Cheney MD, Chen MH, Zhang D, Phillips JG, Loffredo MJ, D'Amico AV. Greatest percentage of involved core length and the risk of death from prostate cancer in men with highest Gleason score ≥ 7. Clin Genitourin Cancer 2014. PubMed
  • Aizer AA, Chen MH, Parekh A, Choueiri TK, Hoffman KE, Kim SP, Martin NE, Hu JC, Trinh QD, Nguyen PL. Refusal of curative radiation therapy and surgery among patients with cancer. Int J Radiat Oncol Biol Phys 2014. PubMed
  • Aizer AA, Falit B, Mendu ML, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Trinh QD, Alexander BM, Nguyen PL. Cancer-specific outcomes among young adults without health insurance. J Clin Oncol 2014. PubMed
  • Keane FK, Chen MH, Zhang D, Loffredo MJ, Kantoff PW, Renshaw AA, D'Amico AV. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer 2014. PubMed
  • Martin NE, Chen MH, Beard CJ, Nguyen PL, Loffredo MJ, Renshaw AA, Kantoff PW, D'Amico AV. Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer 2014; 2014:912943. PubMed
  • Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease. Eur Urol 2013. PubMed
  • Hattangadi JA, Chen MH, D'Amico AV. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death. BJU Int 2012. PubMed
  • Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol 2012; 188:1151-6. PubMed
  • Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM). BJU Int 2012; 110:973-9. PubMed
  • Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res 2011; 108:619-28. PubMed
  • Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2010. PubMed
  • Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH, Force T. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2010; 2:15-25. PubMed
  • Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, Bhatia S, Meeske K, Chen MH, Kinahan KE, Steinberger J, Rosenthal D. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008; 121:e387-96. PubMed
  • Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011-9. PubMed
  • Chen-Plotkin AS, Vossel KA, Samuels MA, Chen MH. Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology 2007; 68:859-61. PubMed
  • Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145:660-4. PubMed
  • Lu HM, Cash E, Chen MH, Chin L, Manning WJ, Harris J, Bornstein B. Reduction of cardiac volume in left-breast treatment fields by respiratory maneuvers: a CT study. Int J Radiat Oncol Biol Phys 2000; 47:895-904. PubMed
  • D'Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA 2015; 314:1291-3. PubMed
  • Chen MH, Kerkela R, Force, T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitors Circulation 2008.
  • Chen MH, Rupnick MA, Chu TF, Force T, Demetri GD. Cardiotoxicity of the tyrosine kinase inhibitor- sunitinib Lancet 2008.
  • Chen MH. Cardiac dysfunction associated with novel targeted anti-cancer therapy: an emerging issue 2009; 11:167-174.
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Ming Hui Chen, MD, MMSc but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members